Benzinga | Dec 8, 2021 08:26AM EST

Actinium Pharmaceuticals, Inc. Announces Participation In Two Panel Discussions At 3rd Targeted Radiopharmaceuticals Summit Dec. 9

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs announced today its participation in the Targeted Radiopharmaceuticals Summit being held virtually December 7 -- 9, 2021. The Targeted Radiopharmaceuticals Summit brings together experts and thought leaders in the field with the goal to achieve meaningful clinical efficacy with theragnostic radionuclide therapies in a mono and combinatorial setting & deliver a robust, cGMP compliant manufacturing supply chain. Representatives from Actinium's R&D and Clinical Development teams have been invited to participate as expert speakers in two panel presentations during the Targeted Radiopharmaceuticals Summit. The panel details are as follows:

Panel: Review of the Last 12 Months of Development of Alpha Emitting Therapies

Session Next Generation Alpha Emitter Based Therapeutics

Actinium Expert Speaker Helen Kotanides, Ph.D., Vice President, Translational Research and Preclinical Development

Date and Time December 9, 2021, 5:30 pm CET, 11:30 am EST

Panel: High Dose -- Low Dose Therapeutic Strategy: Tailoring the Dose of Radiopharmaceuticals for Opportunity and Outcomes

Session Optimizing Treatment Regimens

Actinium Expert Speaker Mary Chen, M.D., Ph.D., Vice President, Clinical Development

Date and Time December 9, 2021, 6:30 pm CET, 12:30 pm EST

Learn more about the Targeted Radiopharmaceuticals Summit at www.targeted-radiopharma.com.